Mission-aligned investors back platform enabling personalized, cross-brand cooking experiences

DUBLIN, Dec. 10, 2025 — Fresco, the platform powering smart cooking experiences for the world’s leading appliance brands, today announced the closing of its Series C funding round of €15 million, backed by a group of investors committed to reshaping the future of food, home cooking, and connectivity. The round includes new investment from Samuel Dennigan (Strong Roots), Barry Napier (Cubic³), and Tyler Hu (Arda), alongside follow-on participation from existing investors Middleby, ACT Venture Capital, AE Ventures, Morpheus Ventures, and Alsop Louie Partners.

The global smart kitchen appliances market is projected to reach approximately USD 60 billion by 2030; however, most appliance brands still lack a way to deliver personalized cooking experiences at scale, a gap that Fresco solves.

The funding will accelerate the evolution of its AI Cooking Companion, a personalized, appliance-aware sous chef that suggests recipes, guides home cooks in real time, and intelligently controls and syncs appliances so meals turn out perfectly, whether through screens, voice, or seamlessly across both. The investment will enable Fresco to scale this experience globally through partnerships with the biggest appliance brands.

The round follows a wave of industry adoption, including new OEM partnerships with E.G.O. and Arda, who manufacture appliances and components for hundreds of global brands. By integrating at this layer, Fresco has the potential to be distributed across every appliance built by these OEMs, enabling onboarding in days rather than months and rapidly extending the reach of Fresco’s cross-brand platform, KitchenOS, and the AI Cooking Companion.

“Almost every part of daily life has been transformed by technology except the kitchen, where the opportunity to help people is arguably the biggest,” said Ben Harris, CEO and co-founder of Fresco. “Fresco already connects all the pieces, positioning us to make AI genuinely useful in the kitchen, personalizing every cooking experience to make it effortless to cook a delicious, healthy meal. And as more partners join the ecosystem, the experience gets better and smarter for everyone.”

Fresco already powers cooking experiences across appliances from global brands, including Panasonic, Instant Pot Brands, Viking, Kenwood, and more, enabling home cooks to enjoy intuitive, guided cooking that works with the devices they own. With this next phase of growth, Fresco is evolving from powering connected appliances to driving intelligent, personalized cooking at scale. 

“As someone who has spent years helping people make better everyday food choices, Fresco feels like the next step. Not just changing what we eat, but how we cook, using technology to make it easier, more personal and more sustainable,” said Samuel Dennigan, who scaled Strong Roots into one of Europe’s leading consumer food brands.

“Fresco is delivering the scale and simplicity this industry has been waiting for-making intelligence in the kitchen invisible, effortless, and deeply personal. It’s the only ecosystem capable of harmonizing hardware, connectivity, and AI to truly transform how we cook,” said Barry Napier, CEO of Cubic³, who led the company through its global automotive connectivity expansion and acquisition.

About Fresco

Fresco is the smart kitchen platform trusted by the world’s leading appliance brands to launch faster, deliver better customer experiences, and accelerate digital transformation. Powered by KitchenOS and the Fresco AI Cooking Companion, the platform connects any appliance across any brand and supports rapid onboarding, global scalability, and 15+ languages. Fresco works with partners including Panasonic, Middleby, Kenwood, Instant Pot Brands, Bosch, GE Appliances, LG, and more, and operates globally from offices in Dublin and Madrid. To learn more, visit frescocooks.com.

SOURCE Fresco

SHANGHAI, Dec. 9, 2025 — D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced the completion of a $108 million Series B financing round.

The funding round was backed by a distinguished group of investors, including IDG Capital and SongQing Capital. Existing investors — WuXi AppTec’s Corporate Venture Fund, Temasek, HSG, MPCi, and Medicxi — also contributed to the round. The robust involvement from both new and current investors highlights widespread confidence in D3 Bio’s innovative pipeline and its global development strategy.

Proceeds from this financing will primarily support the planned global Phase III pivotal program for the company’s lead asset, elisrasib (D3S-001). These pivotal trials will assess elisrasib as both a monotherapy and in combination therapies for KRAS G12C-mutant cancers across key countries and regions, including the United States, China, and the European Union, to facilitate global regulatory submissions.

Furthermore, the funding will facilitate ongoing development of D3 Bio’s comprehensive pipeline of targeted and immuno-oncology programs, which are centred on innovative mechanisms with first-in-class or best-in-class potential.

Dr. George Chen, Founder, Chairman, and CEO of D3 Bio, stated, “The completion of our Series B financing demonstrates the strong confidence our investors place in our vision, scientific approach, business operations, and global development capabilities. This funding enables us to advance our lead program into late-stage clinical trials and further expand our pipeline of innovative therapies designed to benefit patients globally.”

Dr. Antoine Yver, Member of the Board of Directors and Scientific Committee of D3 Bio, stated, “This financing demonstrates that the swift and effective pursuit of the best- or first-in-class science is meaningful to society, and validates D3 Bio’s leading innovation, scientific vision and development strategy. It also highlights the unique potential of elisrasib for individuals affected by KRAS G12C-mutant cancers.”

About D3 Bio
D3 Bio is a global biotechnology company focused on the discovery, development, and registration of new medicines in oncology and immunology. The company’s discovery and development platforms leverage proprietary clinical insight and biomarker strategies to create novel and clinically meaningful therapies for patients in need. D3 Bio’s oncology programs target driver mutations or critical immune pathways and are designed to have first-in-class or best-in-class potential. D3 Bio owns global rights for all of its programs.

For more information, please visit www.d3bio.com. 

SOURCE D3 Bio, Inc.

Grant to expand program in Atlanta and strengthen Indianapolis programming

ALEXANDRIA, Va. and INDIANAPOLIS, Dec. 9, 2025 — CHC: Creating Healthier Communities (CHC) today announced an additional $700,000 in funding from Elevance Health Foundation to expand the reach of its Better Births Initiative (BBI)—a nationally recognized program improving maternal health outcomes and reducing the high rates of preterm births in under-resourced communities.

Many women face a higher risk of preterm birth and complications during pregnancy. In fact, one out of every 2,000 Black women die during childbirth, a rate roughly 2.7 times higher than the national average. By partnering with community-based organizations, the BBI program improves access to reproductive health care, addresses social drivers of health, and strengthens support systems for expectant mothers.

Proven Impact on Maternal Health
Since launching in 2022, BBI has delivered measurable improvements in maternal health outcomes:

• Program participants carried pregnancies to full term at a rate of 91.2%, compared to 85.3% nationally for the program’s target population – an improvement of approximately six percentage points.
• The average delivery occurred at 38.5 weeks, with nearly all preterm births occurring in the moderate-to-late preterm range.
• Participants experienced a 70% reduction in anxiety symptoms from intake to program completion.
• The program has connected more than 360 mothers with trained doulas and comprehensive prenatal support.

“For nearly 70 years, CHC has partnered with thousands of organizations to improve health and well-being in communities across the country,” said Demetrius Geiger, Program Manager, CHC: Creating Healthier Communities. “We are grateful to Elevance Health Foundation for their continued commitment to this work and the leadership of our partners. We are strengthening a maternal health ecosystem that delivers meaningful, lasting results for families and sets a new standard for coordinated care.”

Expanding Community-Based Maternal Care in Atlanta
Building on this success, CHC will expand BBI services to reach up to 300 more pregnant women in Atlanta through an integrated doula and community health worker coordinated care model, providing both birth-related and social support services. CHC will also expand its core evaluation measures to include elective and emergent delivery outcomes, hospital readmissions, and neonatal intensive care unit (NICU) admissions, vital measures that reveal risks, highlight opportunities, and drive life-saving improvements in maternal care. Expanded eligibility requirements will ensure that more expectant mothers receive timely, comprehensive care.

Scaling Innovative Solutions in Indianapolis
In Indianapolis, CHC’s Community Leadership Action Board (CoLAB) has united cross-sector partners, doulas, and community voices to identify urgent gaps in maternal care. With renewed backing from the Elevance Health Foundation, this collaboration has produced actionable solutions, including strengthening referral systems, building workforce capacity, and now driving the next phase of maternal health innovation in the city.

Through the CoLAB, CHC is advancing a systems-level maternal health model. Partnerships will strengthen and align referral systems, embed social determinants of health into maternal supports, and expand the capacity of local community-based organizations. This collaborative approach ensures that 180 pregnant women receive seamless access to essential services spanning from housing, food, transportation, and behavioral health, and childcare, while creating a foundation for lasting improvements in maternal outcomes, helping ensure women and their babies achieve optimal health and well-being.

“Elevance Health Foundation is committed to addressing the root causes of maternal health disparities,” said Shantanu Agrawal, MD, Chief Health Officer of Elevance Health. “Our continued partnership with CHC reflects our belief in community-led innovation, solutions that elevate doulas, strengthen referral networks, and set a new benchmark for maternal health nationwide.”

Since 2015, the Elevance Foundation has invested in maternal health programs ranging from prenatal care to mental health support. By funding programs like CHC’s Better Births Initiative, Elevance Health Foundation drives meaningful, measurable change in communities, supporting innovative solutions and empowering organizations to tackle critical health challenges.

About CHC: Creating Healthier Communities
For nearly 70 years, CHC: Creating Healthier Communities has united nonprofits, businesses, and communities to drive scalable impact that improves lives and strengthens communities. With a network of 5,000+ partners nationwide, CHC addresses the barriers to health so every person, no matter their zip code, can live their healthiest life. Join us at chcimpact.org or follow us on social media @chcimpact

About Elevance Health Foundation
Elevance Health Foundation is the philanthropic arm of Elevance Health Inc. The Foundation works to improve the health of the socially vulnerable through partnerships and programs in our communities with an emphasis on maternal-infant health; behavioral health; and food as medicine. Through its key areas of focus, the Foundation also strategically aligns with Elevance Health’s focus on community health and becoming a lifetime, trusted health partner that is fueled by its purpose to improve the health of humanity. To learn more about Elevance Health Foundation, please visit or follow us @ElevanceFND on X and Elevance Health Foundation on Facebook.

SOURCE Creating Healthier Communities

NEW YORK, Dec. 9, 2025 — Radial today announced the company has raised $50 million in venture funding to create access to the world’s most advanced mental health treatments. The company is backed by General Catalyst, who led the Series A, and additional investors Solari Capital, JSL Health Capital, Founder Collective, BoxGroup, Scrub Capital, and Diede van Lamoen.

New brain medicines – treatments like neuromodulation (e.g. accelerated transcranial magnetic stimulation, (TMS)) and rapid-acting medications (e.g. Spravato) that directly heal the brain – are achieving far better outcomes for patients with mental health conditions. These treatments work in days to weeks, with some studies showing remission rates as high as 78%. However, the current healthcare system is designed to deliver long-term medication-based management, not the more episodic interventional brain medicine supported by modern evidence. Further, the system does not measure outcomes, which limits payors ability to pay for the best care possible, and clinicians lack the best clinical decision support and operational tools to enable these new forms of care at scale.

Radial is addressing this problem for patients, providers, and payers by developing clinical infrastructure, reimbursement tools, and decision support that’s designed around modern brain medicine. The company is building a national network of clinics that accept most major forms of insurance, including Medicare, Tricare, VA-CCN, Aetna, Cigna, United, and many Blues plans. For patients, this means the most effective combination of therapies are available to everyone who needs them. For clinicians, this means focusing on providing that care. And, for payors, this means better outcomes and less ultimate cost for even the most complex patients.

John Capecelatro, CEO and co-founder of Radial, commented, “People who are struggling with mental health can’t wait years to see if something might help through trial and error. New rapid-acting treatments work in days or weeks instead of years. We’re seeing remission rates for depression of 50-60% and as high as 78% in some studies our team has co-authored. The healthcare system hasn’t caught up. Radial is here to change that. When we have tools for the right clinical workflows and insurance pathways, people can access therapies that help them get better far sooner. It’s a dramatic difference for individuals, for families, and for the health system that ends up carrying the cost when care drags on without results.”

Reva Nohria, Partner at General Catalyst, said, “Psychiatry is undergoing a transformation, but most of that progress hasn’t reached patients. The science is there, yet the infrastructure to deliver modern, brain-based treatments at scale is still missing. Radial understands both the clinical evidence and the operational complexity required to close that gap. We believe this work can meaningfully expand access to effective mental health care.”

Owen Muir, Chief Medical Officer at Radial, added, “In research, we’ve proven that these powerful treatments work. They change lives. The hard part has always been bringing them into everyday clinical practice. Radial was built to close that gap. We’re taking what we know from years of clinical research and turning it into care that any patient can access. Radial is focused on the care patients have long deserved.”

Radial currently operates with seven clinics in six states, supported by its proprietary software platform. This fundraising will support the company’s plans to expand nationally in 2026, growing both its clinic network and technology partnerships.

About Radial
Radial is expanding access to the world’s most advanced mental health treatments by Radial is developing clinical infrastructure, reimbursement tools, and AI-guided decision support designed around novel psychiatry treatments like neuromodulation (e.g. TMS), medication (e.g. Spravato), and other interventional therapies. Their goal is to make transformative brain medicine accessible to all. Learn more at www.meetradial.com.

Media Contact:
Jacquelyn Miller
‪415-745-1794
[email protected]

SOURCE Radial

PHOENIX, Dec. 9, 2025 — Cloverleaf Networks, a leading provider of next-generation connectivity, cybersecurity, and collaboration solutions for modern workforces, today announced a strategic venture capital investment from Super K Ventures, a prominent early-stage technology investor known for backing high-growth companies transforming the digital infrastructure landscape.

This investment marks a significant milestone in Cloverleaf Networks’ mission to deliver a more resilient, intelligent, and customer-centric approach to business connectivity. The new funding will accelerate product innovation across the company’s flagship offerings—including Cloverleaf Connect, Cloverleaf Anywhere, Cloverleaf SASE, and collaboration platform Ryver—while expanding market reach in the United States and abroad.

“Super K Ventures’ investment is a strong validation of our vision to modernize business connectivity and cybersecurity through simplicity, transparency, and an unmatched customer experience,” said Joe Faherty, Founder & CEO of Cloverleaf Networks. “This partnership positions us to scale faster, innovate deeper, and deliver even greater value to the organizations that rely on Cloverleaf every day.”

Super K Ventures brings deep expertise in scaling B2B infrastructure, SaaS, and cloud-native technology firms. Their support will help Cloverleaf Networks accelerate hiring in engineering, product development, and customer success, while also expanding its national footprint of managed service capabilities.

“Cloverleaf Networks is redefining how companies connect, protect, and manage their distributed workforce environments,” said Renee Klenert, Managing Partner at Super K Ventures. “The combination of their technology, customer-centric culture, and operational excellence represents exactly what we look for in a long-term partner.”

Cloverleaf Networks’ SaaS platform CLOE remains a core differentiator, providing centralized visibility, proactive monitoring, and simplified network management from a single intuitive interface. CLOE will expand its AI-driven analytics and automation capabilities, empowering IT teams to maintain network health and security in real time.

About Cloverleaf Networks

Cloverleaf Networks provides fully managed, secure, cloud-optimized connectivity solutions for remote, hybrid, and multi-site businesses. Headquartered in Phoenix, Arizona, Cloverleaf delivers internet, SD-WAN, cybersecurity, and collaboration services powered by its CLOE operations platform and backed by the Emerald Service Commitment.

About Super K Ventures

Super K Ventures is a venture capital firm focused on early-stage investments in high-growth technology companies. With an emphasis on digital infrastructure, enterprise software, and AI-driven platforms, Super K Ventures partners with visionary founders to accelerate innovation and scale transformative businesses.

SOURCE Cloverleaf Networks

Opine’s new funding, led by S3 Ventures, solves a decades-old problem for companies selling complex solutions, where selling and delivering their solutions requires detailed multi-department synchronization.

RALEIGH, N.C., Dec. 9, 2025 — Opine announced today that it has raised five million USD in new financing led by S3 Ventures of Austin, Texas, with participation from Knoll Ventures, Atlanta Seed Company, Gray Ventures, Propel Ventures, Triangle Tweener Fund, and Feross Aboukhadijeh, CEO of Socket.dev. This investment comes after Opine recorded 10x revenue growth in 2025, establishing itself as a rapidly growing market necessity. The capital will accelerate development of Opine’s unified AI-native workspace designed to streamline the entire technical sales cycle from initial discovery to post-sale delivery for complex B2B technology vendors.

Complex enterprise deals often span multiple departments, rely on an array of unconnected tools, and are hampered by siloed conversations. Solution engineers spend hours rebuilding context, leaders lack visibility into deal risks, and post-sales teams often inherit customers without knowing what was promised. Opine was created to fix this by bringing every team, data source, and process into a single intelligent workspace that surfaces risks early, automates repetitive work, captures every evaluation and handoff accurately, and keeps everyone aligned throughout the customer lifecycle.

“We’re excited to use this funding to continue to grow and support our innovative customers. They’re building and selling some of the most sophisticated B2B solutions available and need a unified AI-native system that understands their market and supports all the effort that goes into winning complex deals. This investment allows us to deepen our AI capabilities, advance our product, and expand our go-to-market reach,” said Akash Ganapathi, CEO and co-founder of Opine.

“We are thrilled to be backing the Opine team. After we spoke to executives at multiple customers, it became clear that Opine’s AI-native platform consistently makes sales, customer success, and product teams more effective at winning new business and delivering value,” said Eric Engineer, Partner at S3 Ventures.

“Since switching to Opine earlier this year, we’ve gained clearer opportunity insights, faster answers, and tighter team alignment, often cutting out a 30-minute call with a single question. We’re excited to expand our use of their playbooks and to see what the team builds next with their new funding,” said Mark Rida, Director of Solutions Engineering (Opine customer).

“The Opine team really understands the challenges of presales teams at scale. You can feel it in how they’ve built their product and with every interaction with their team. We’re happy to be able to deliver an excellent working experience to our prospects and customers,” shared Jaime Lewis-Gross, SVP, Sales Engineering (Opine customer).

Opine plans to use the capital to advance workflow automation, real-time deal intelligence, and unified data infrastructure. The company will also expand its market presence as technical sales becomes one of the most strategic functions in modern B2B organizations.

About Opine

Opine is an AI-native workspace built for technical sales teams, connecting presales to post-sales in one intelligent system. By automating workflows, surfacing real-time insights, and bringing every stakeholder together, Opine helps revenue-critical teams move faster, sell smarter, and deliver lossless customer handoffs. The platform replaces spreadsheets, tribal knowledge, and manual updates with a unified solution that reflects how technical sales actually operates. Founded in Raleigh, Opine is trusted by leading B2B companies to close complex deals with clarity and precision across an ever-increasingly complex and fast-moving world. Learn more about Opine at www.tryopine.com 

About S3 Ventures

Founded in 2005, S3 Ventures is one of the largest and longest-serving venture capital firms based in Texas, but investing nationwide. Backed by a philanthropic family with a multi-billion-dollar foundation, we empower visionary founders with the patient capital and true resources required to grow extraordinary, high-impact companies in Business Software and Healthcare Technology. With over $1B in assets under management, we lead Seed, Series A, and Series B rounds, with initial investments ranging from $500K to $15M and the capacity to invest $25M over the life of a company. Learn more at www.s3vc.com.

CONTACT: Nate Meadows; Head of Marketing, Opine; [email protected]

SOURCE Opine

SAN FRANCISCO, Dec. 9, 2025 — PhyxUp Health, an AI-driven Remote Therapeutic Monitoring (RTM) platform founded by a former physical therapist and Harvard graduate, is transforming how rehabilitation clinics operate throughout the United States. Built as a next-generation patient management and engagement solution, PhyxUp enables clinics to remotely monitor patient progress, increase therapy adherence, and streamline communication beyond the clinic walls. The platform incorporates automated documentation and integrated RTM billing, ensuring clean reimbursement workflows that help outpatient practices boost both patient outcomes and revenue while avoiding additional administrative burden.

Overcoming Structural Limitations in the Rehabilitation Market

Rehabilitation clinics, including physical therapy, occupational therapy, and speech therapy providers, face heavy administrative burdens that reduce the amount of time clinicians can dedicate to direct patient care. PhyxUp Health addresses this challenge through a unified workflow that enables clinics to remotely monitor and communicate with patients between visits while automating tasks such as billing, documentation, eligibility verification, and onboarding. By enhancing patient engagement and outcome tracking, PhyxUp equips therapists with real-time insights that support more informed clinical decisions between visits. The platform’s AI-driven analytics also help identify risk factors, assess adherence, and guide patients toward more efficient recovery pathways.

Technological Innovation in AI-Powered RTM 

PhyxUp Health delivers an end-to-end B2B SaaS platform that enables physical therapy practices to provide continuous, between-visit patient care while unlocking new reimbursement through RTM:

• AI-Driven Patient Monitoring: Automatically analyzes symptoms and exercise activity to catch issues early and alert providers when patients need attention.
• Automated Documentation & Billing: Automatically generates all RTM documentation and completes the full billing process for the clinic, minimizing administrative work.
• Fully Managed RTM Service: Licensed remote physical therapists handle patient monitoring and follow-ups for the clinic, delivering a hands-off RTM service.

Growing Adoption Across the United States

PhyxUp Health is experiencing rapid adoption as more clinics transition to digital-first and data-enabled patient care models. The platform is now utilized by independent private practices, multi-location clinic networks, and hospital-affiliated outpatient departments. Adoption by a Harvard Medical School-affiliated provider, along with collaboration with the Marcus Institute for Aging Research, validates PhyxUp Health’s clinical credibility and reinforces its trusted role within the evolving digital rehabilitation ecosystem.

Future Growth Strategy

Following its pre-seed investment in 2024, PhyxUp Health is preparing for a $1M seed raise to support the next stage of its U.S. growth. Over the coming year, the company plans to expand its RTM operations nationwide, enhance its partnerships with practice management systems, and build more advanced AI tools that help clinics anticipate patient outcomes and identify potential issues earlier. As more rehabilitation providers adopt technology to improve continuity of care, PhyxUp Health is emerging as an important infrastructure partner in the digital rehab market.

About PhyxUp Health

PhyxUp Health, founded by CEO Sangwon Lim, a former physical therapist and Harvard graduate, has emerged as one of the leading AI-powered Remote Therapeutic Monitoring (RTM) platforms in the U.S. The company supports physical therapy clinics and hospitals – including a Harvard Medical School affiliate – by providing a fully automated, end-to-end RTM service that includes patient monitoring, follow-ups, and billing. PhyxUp Health is currently raising a $1M seed round to accelerate product development and nationwide expansion.

For more information, visit https://phyxuphealth.com/

SOURCE PhyxUp Health

Funding from Khosla Ventures and SeaX Ventures follows FDA clearance and RSNA 2025 debut; company advances toward commercial deployment

BOSTON, Dec. 9, 2025 — a2z Radiology AI, developer of AI systems for comprehensive medical imaging interpretation, today announced a $4.5M seed round with participation from Khosla Ventures and SeaX Ventures. The funding will accelerate commercial deployment of the company’s FDA-cleared triage system and continued R&D toward broader imaging interpretation capabilities.

The investment comes on the heels of two milestones: FDA clearance for a2z-Unified-Triage, the first system to simultaneously triage seven urgent conditions on abdomen-pelvis CT scans in the U.S. market, and the company’s debut at RSNA 2025, where it presented the first prospective study evaluating AI-assisted preliminary report drafting for abdomen-pelvis CT.

That study demonstrated that AI assistance reduced reporting time by 17.8%, increased radiologist confidence by 14.8%, and decreased mental demand by 22.4%—while improving detection of findings without increasing false positives. The results offer early evidence that comprehensive AI can meaningfully improve both accuracy and efficiency, addressing longstanding questions about the real-world value of radiology AI.

“Radiology is one of the areas that will benefit the most from AI, ensuring no disease goes undetected,” said Vinod Khosla of Khosla Ventures. “While others focus on single conditions, a2z is able to evaluate imaging for a broad range of issues, bringing us closer to the comprehensive capabilities of a real-life radiologist.”

“Radiology is central to modern medicine, but delays can slow down care when timely answers are essential,” said Dr. Kid Parchariyanon, Founder and Managing Partner of SeaX Ventures. “a2z is meeting this challenge with technology that brings expert-level support directly to clinicians. We’re proud to support a2z as they build the tools that make a meaningful difference for providers and patients worldwide.”

With imaging demand outpacing the radiology workforce, clinicians face growing wait times for reads that guide critical decisions. Abdomen-pelvis CT alone accounts for over 20 million exams annually in the U.S.—the highest-volume CT category. a2z’s approach differs from existing AI solutions that address single conditions: the company is building toward systems that can evaluate imaging comprehensively, the way radiologists actually work.

“The response at RSNA validated what we’ve been building—AI that considers everything from A to Z in each study,” said Pranav Rajpurkar, PhD, co-founder of a2z Radiology AI and Associate Professor at Harvard Medical School. “This funding lets us keep pushing on R&D while bringing our cleared technology to the care teams who need it.”

“We’re building toward comprehensive interpretation of complex imaging studies at a level that simply hasn’t existed before,” said Samir Rajpurkar, co-founder and CEO.

The funding will support partnerships with health systems, continued product development, and commercial rollout in 2026.

About a2z Radiology AI

a2z Radiology AI is building the intelligence layer for medical imaging, making radiologist-level interpretation accessible on demand. The company develops AI systems that provide immediate answers to questions about CT scans, starting with comprehensive abdomen-pelvis analysis and expanding across imaging modalities and anatomies. Founded in 2024, a2z was co-founded by Pranav Rajpurkar, an Associate Professor at Harvard Medical School and pioneer in generalist medical AI, and Samir Rajpurkar, a technology industry veteran. a2z-Unified-Triage is FDA-cleared and available for clinical deployment.

For more information, visit https://a2zradiology.ai

About Khosla Ventures

Khosla Ventures is a venture capital firm focused on investments in artificial intelligence, financial services, healthcare, consumer, enterprise, and sustainability. It is known for making early capital investments in startups such as OpenAI, Guardant Health, Instacart, Affirm, DoorDash, and Block.

For more information, visit https://www.khoslaventures.com/

About SeaX Ventures

SeaX Ventures is a global venture capital firm dedicated to investing in deep-tech startups shaping the future through groundbreaking innovations. With a mission to empower entrepreneurs building exponential technologies, SeaX Ventures focuses on sectors with high potential to drive meaningful economic and environmental impact. SeaX leverages relationships with over 500 listed companies, multinationals, and major family businesses in Southeast Asia to support portfolio companies.

For more information, visit https://seaxventures.vc

Media Contact

[email protected]

SOURCE a2z Radiology AI

Oversubscribed round demonstrates strong investor confidence in Lin Health’s neuroscience-based approach to chronic pain

DENVER, Dec. 9, 2025 — Lin Health, the leader in behavioral care for chronic pain recovery, today announced the close of an oversubscribed $11 million Series A financing round. The round was led by Proofpoint Capital, a U.S.-based venture firm formed by seasoned healthcare operators, with participation from new investors Osage Venture Partners and NewHealth Ventures. Continued strong support and investment came from existing investors, including aMoon, Mayo Clinic, Saban Ventures, Shoni Health Ventures, and Viola Ventures.

In partnership with major health systems, clinics, and payers, Lin Health is redefining chronic pain care to treat conditions as diverse as migraines, irritable bowel syndrome (IBS), and back and joint pain. Accessible to more than 60 million covered Americans, Lin offers patients an effective, non-opioid treatment that addresses the root cause of pain in the nervous system. Through a physician-led, coach-supported virtual program, Lin engages patients multiple times per week as a high-touch resource grounded in decades of clinical research and aligned with national guidelines for chronic pain management.

“This milestone reflects the confidence of our investors and the urgency of addressing our growing chronic pain crisis, as at least one in five doctor visits are tied to pain,” said Lin Health CEO and Co-Founder Yehuda Kogan. “We’ve proven that our mission-driven team and model deliver results for patients, systems, and payers, and now we’re ready to compound our rapid growth, scale our partnerships, and bring relief to the millions of underserved Americans living with these conditions.”

The company operates with a proven collaborative care model, leveraging its technology and AI software to scale operations and support patients and clinicians efficiently without increasing administrative costs, while deepening integration across the healthcare ecosystem. The new funding will be used to drive product innovation, expand go-to-market efforts, strengthen clinically integrated partnerships, and accelerate Lin’s role as the first-line solution for chronic pain care nationwide.

“Lin Health has built a category-defining approach to chronic conditions as they tackle one of the most costly and overlooked challenges in U.S. healthcare: chronic pain,” said Dan Goldsmith of Proofpoint Capital, who joins Lin Health’s board. “Their model doesn’t just deliver meaningful outcomes for patients; it also addresses systemic inefficiencies and financial realities for payers and care teams. I’ve seen firsthand how the right combination of technology and clinical expertise can transform an industry, and Lin is poised to do just that for pain care. I’m excited to join the board and support the team in scaling this important mission.”

About Lin Health

Lin Health tackles the biggest blind spot in U.S. healthcare: chronic pain, which costs more than cancer and diabetes combined at $635 billion annually. Our evidence-based, award-winning treatment retrains maladaptive pain circuits and restores function, bridging medical and behavioral care through elements of Pain Reprocessing Therapy, Emotional Awareness and Expression Therapy, Cognitive Behavioral Therapy, and other neuroplastic pain recovery techniques. Our adjunctive care improves population health, reduces provider burnout, supports value-based outcomes, lowers the total cost of care, and prevents system leakage. Founded in 2021 by industry veterans and backed by leading investment firms, we partner with health systems, clinics, and payers to deliver immediately accessible continuity of care, built on end-to-end proprietary software that handles the entire business side of care delivery. With nationwide payer coverage for 60 million Americans, Lin is on a mission to reclaim lives from chronic pain.

Learn more at www.lin.health

Media Contact:

[email protected] 

SOURCE Lin Health